这些结果表明了BRCA1-BARD1-RAD51复合体在通过同源重复修复DNA损伤方面的中心作用。 “确定基于BRCA的DNA修复通路的具体机制将帮助科学家们设计出更为有效地杀灭癌细胞的药物,”Sung 博士说:“而且了解这一机制将给予医生们预测患者癌症风险的能力。” 参...
[1]. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416. doi:10.1001/jama.2017.7112 [2]. Walsh T, Gulsuner S, Lee MK, et al. Inherited predisposition to breas...
[4]Hu C, Hart SN, Polley EC, et al. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA. 2018;319(23):2401-2409. doi:10.1001/jama.2018.6228 [5]Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl C...
Assessing the risk of uterine serous carcinoma in survivors of triple negative breast cancer: Is BRCA1 the link? 评估三阴性乳腺癌幸存者患子宫浆液性癌的风险:BRCA1是联系吗? First Author: William Manning Background Uterine ...
而在2017年发表在JAMA杂志上的一项前瞻性研究利用英国家庭医生的制度,在1997-2011年间共纳入9856名女性(其中6036名女性是BRCA1突变,3820名女性是BRCA2突变),通过中位随访5年的时间,回答了这个问题。 (Kuchenbaecker K B, Hopper J L, Barnes D R, et al. Risks of breast, ovarian, and contralateral breast...
[4]Hu C, Hart SN, Polley EC, et al. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA. 2018;319(23):2401-2409. doi:10.1001/jama.2018.6228 [5]Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl ...
本研究采用回顾性队列分析对来自21个国家或中心的5707名BRCA1和3535名BRCA2携带者的前瞻性随访研究数据进行跟踪研究。 了解华大基因产前诊断,胚胎植入前诊断多种产品信息>>> 原文检索:The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations ...
Geyer CE Jr, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022 Oct 10:S0923-7534(22)04165-5. doi: 10.1016/j.annonc.2022.09.159...
Cancer Causes & Control . 2005 (6)Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers[J] . Joanne Kotsopoulos,Jan Lubinski,Henry T. Lynch,Susan L. Neuhausen,Parviz Ghadirian,Claudine Isaacs,Barbara Weber,Charmaine Kim-Sing,William D. Foulkes,Ruth Gershoni-...
: a phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. Presented at: 2021 ASCO Annual Meeting; June 4-8, 2021; Virtual. Abstract LBA1....